Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
ERK1/2 signaling induces skeletal muscle slow fiber-type switching and reduces muscular dystrophy disease severity
Justin G. Boyer, … , Sakthivel Sadayappan, Jeffery D. Molkentin
Justin G. Boyer, … , Sakthivel Sadayappan, Jeffery D. Molkentin
Published April 9, 2019
Citation Information: JCI Insight. 2019;4(10):e127356. https://doi.org/10.1172/jci.insight.127356.
View: Text | PDF
Research Article Muscle biology

ERK1/2 signaling induces skeletal muscle slow fiber-type switching and reduces muscular dystrophy disease severity

  • Text
  • PDF
Abstract

MAPK signaling consists of an array of successively acting kinases. ERK1 and -2 (ERK1/2) are major components of the greater MAPK cascade that transduce growth factor signaling at the cell membrane. Here, we investigated ERK1/2 signaling in skeletal muscle homeostasis and disease. Using mouse genetics, we observed that the muscle-specific expression of a constitutively active MEK1 mutant promotes greater ERK1/2 signaling that mediates fiber-type switching to a slow, oxidative phenotype with type I myosin heavy chain expression. Using a conditional and temporally regulated Cre strategy, as well as Mapk1 (ERK2) and Mapk3 (ERK1) genetically targeted mice, MEK1-ERK2 signaling was shown to underlie this fast-to-slow fiber-type switching in adult skeletal muscle as well as during development. Physiologic assessment of these activated MEK1-ERK1/2 mice showed enhanced metabolic activity and oxygen consumption with greater muscle fatigue resistance. In addition, induction of MEK1-ERK1/2 signaling increased dystrophin and utrophin protein expression in a mouse model of limb-girdle muscle dystrophy and protected myofibers from damage. In summary, sustained MEK1-ERK1/2 activity in skeletal muscle produces a fast-to-slow fiber-type switch that protects from muscular dystrophy, suggesting a therapeutic approach to enhance the metabolic effectiveness of muscle and protect from dystrophic disease.

Authors

Justin G. Boyer, Vikram Prasad, Taejeong Song, Donghoon Lee, Xing Fu, Kelly M. Grimes, Michelle A. Sargent, Sakthivel Sadayappan, Jeffery D. Molkentin

×

Figure 1

Constitutive active MEK1 expression leads to an increase in type I fibers.

Options: View larger image (or click on image) Download as PowerPoint
Constitutive active MEK1 expression leads to an increase in type I fiber...
(A) Western blotting of total ERK1/2 protein in the soleus muscle compared with the quadriceps muscle from 3 independent wild-type animals at 3 months of age. GAPDH is shown as loading control. (B) Schematic representation of the constitutively active MEK1 cDNA targeted to the Rosa26 locus with a stop cassette and flanking loxP sites (blue), whereby Cre recombination gives expression. (C) Western blot analysis for the indicated proteins using gastrocnemius (gastroc) lysate from 6-month-old mice of the indicated genotypes. Results from 3 different mice are shown. (D) Representative image of the extensor digitorum longus (EDL) muscles from 6-month-old Rosa26-MEK1 and Rosa26-MEK1Myl1–cre mice. (E) Relative muscle weights (MW) of quadriceps (quad), gastroc, and tibialis anterior (TA) muscles normalized to tibia length (TL) from 6-month-old Rosa26-MEK1Myl1–cre mice, n = 6; Myl1-cre, n = 4; and Rosa26-MEK1, n = 4. One-way ANOVA with Tukey’s multiple comparisons test was used to determine significance, *P < 0.05 versus controls. Data are plotted as the mean and the error bars represent SEM. (F and G) Quantification of slow, oxidative type I fibers across an entire muscle histological section at the mid-belly from the TA and EDL taken from 6-month-old mice of the indicated genotypes. EDL and TA for Rosa26-MEK1, n = 3; EDL for Rosa26-MEK1Myl1–cre, n = 6; and TA for Rosa26-MEK1Myl1–cre, n = 4. A 2-tailed t test was used to analyze groups for statistical significance. *P < 0.05 versus Rosa26-MEK1. Data represent mean ± SEM. (H) Representative histological sections from the EDL muscle immunostained for Myh7 (type I myosin) protein (red) and laminin (blue) from mice of the indicated genotypes. Scale bars: 500 μm. (I) mRNA levels for Myh7, troponin I1 (Tnni1), troponin C1 (Tnnc1), troponin T1 (Tnnt1), and sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (Atp2a2) from the EDL muscle from 6-month-old mice of the indicated genotypes. Data are plotted as the mean ΔCt for each genotype and fold changes calculated using the ΔΔCt method are indicated above the results for each transcript tested. Error bars represent SEM. Fold-change ranges are provided in Supplemental Table 1. n = 4 for both groups. Significance was determined using a 2-tailed t test, *P < 0.05.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts